CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Updates on CADTH reimbursement reviews are posted to this page. Reports are searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them, and appropriate credit is given to CADTH.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | June 30, 2004 | January 26, 2005 |
| NovoMix 30 | Insulin aspart/insulin aspart protamine | Diabetes mellitus | Do not list | Complete | October 13, 2005 | April 26, 2006 |
| Fosavance 70/5600 | Alendronate sodium / cholecalciferol | Osteoporosis | List in a similar manner to other drugs in class | Complete | December 18, 2008 | June 17, 2009 |
| Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | November 6, 2009 | April 27, 2010 |
| Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | October 1, 2013 | October 22, 2014 |
| Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | March 29, 2011 | July 18, 2011 |
| Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | January 6, 2014 | December 19, 2014 |
| Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | June 30, 2011 | December 16, 2011 |
| Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | July 20, 2011 | November 16, 2011 |
| Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | List with clinical criteria and/or conditions | Complete | November 29, 2007 | June 25, 2008 |
| Actemra | Tocilizumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | January 30, 2012 | July 19, 2012 |
| Actemra | Tocilizumab | Arthritis, polyarticular juvenile idiopathic | List with criteria/condition | Complete | July 29, 2013 | March 19, 2014 |
| Actemra | Tocilizumab | Arthritis, rheumatoid | List with criteria/condition | Complete | March 3, 2014 | February 19, 2015 |
| Actemra | Tocilizumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | May 27, 2010 | November 17, 2010 |
| Actemra | tocilizumab | Giant cell arteritis (GCA) | Reimburse with clinical criteria and/or conditions | Complete | September 25, 2017 | March 27, 2018 |
| Actikerall | Fluorouracil and Salicylic Acid | Hyperkeratotic actinic keratosis | Reimburse with clinical criteria and/or conditions | Complete | August 31, 2016 | March 22, 2017 |
| Adcirca | Tadalafil | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete | February 5, 2010 | July 15, 2010 |
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Withdrawn | December 15, 2004 | ||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Do not list | Complete | April 13, 2004 | November 24, 2004 |
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder, Adult | Do not list | Complete | November 29, 2007 | June 25, 2008 |
| Adempas | Riociguat | Chronic thromboembolic pulmonary hypertension | List with criteria/condition | Complete | September 30, 2013 | July 17, 2014 |
| Adempas | Riociguat | Pulmonary arterial hypertension (WHO group 1) | List with clinical criteria and/or conditions | Complete | June 25, 2015 | December 17, 2015 |
| Adlyxine | lixisenatide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | May 29, 2017 | November 23, 2017 |
| Admelog | Insulin lispro | Cancelled | ||||
| Advicor | Niacin/lovastatin | Hypercholesterolemia and mixed dyslipidemia | List | Complete | October 18, 2005 | April 26, 2006 |
| Aermony RespiClick | fluticasone propionate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | October 4, 2017 | December 19, 2018 |
| Zenhale (inhalation aerosol) | Mometasone furoate and formoterol | Asthma | Do not list | Complete | February 16, 2011 | September 28, 2011 |
| Afinitor | Everolimus | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex | Do not list | Complete | March 19, 2014 | April 15, 2015 |
| Afinitor | Everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | Do not list | Complete | March 8, 2013 | September 25, 2013 |
| Aimovig | erenumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | May 2, 2019 | July 22, 2020 |
| Ajovy | fremanezumab | migraine | Active | June 3, 2020 | ||
| Akynzeo | netupitant / palonosetron | Nausea and vomiting (chemotherapy induced) prevention | Reimburse with clinical criteria and/or conditions | Complete | December 8, 2017 | June 20, 2018 |
| Aldurazyme | Laronidase | Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie | Do not list | Complete | February 3, 2005 | July 14, 2005 |
| Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | February 6, 2015 | ||
| Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete | October 5, 2012 | May 15, 2013 |
| Aloxi (capsule) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list | Complete | October 5, 2012 | April 24, 2013 |
| Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | June 22, 2006 | November 15, 2006 |
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | October 26, 2006 | ||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | March 26, 2007 | June 14, 2007 |
| Alvesco | Ciclesonide | asthma | List | Complete | July 24, 2006 | December 20, 2006 |
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | February 28, 2006 | September 27, 2006 |
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | November 16, 2004 | May 26, 2005 |
| Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | August 19, 2019 | July 22, 2020 |
| Braftovi and Mektovi | encorafenib and binimetinib | Advanced Melanoma | Active | December 16, 2020 | ||
| Anoro Ellipta | Umeclidinium/vilanterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | February 26, 2014 | January 15, 2015 |
| Apidra | Insulin glulisine | Diabetes, Mellitus (Type 1 & 2) | List in a similar manner to other drugs in class | Complete | August 29, 2008 | February 19, 2009 |
| Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | April 27, 2012 | March 27, 2013 |
| Aptiom | Eslicarbazepine acetate | Epilepsy, partial-onset seizures | List with criteria/condition | Complete | August 15, 2014 | April 16, 2015 |
| Aptivus | Tipranavir | HIV infection | List with clinical criteria and/or conditions | Complete | December 15, 2005 | May 17, 2006 |
| Arbesda RespiClick | fluticasone propionate / salmeterol xinafoate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | October 4, 2017 | December 19, 2018 |
| Arnuity Ellipta | Fluticasone furoate | Asthma | List with criteria/condition | Complete | June 26, 2015 | December 17, 2015 |
| ASMANEX | Mometasone furoate | Asthma | List | Complete | November 10, 2011 | May 16, 2012 |
| Atectura Breezhaler | indacaterol /mometasone furoate | Asthma maintenance (adults, children 12 or older) | Reimburse with clinical criteria and/or conditions | Complete | May 19, 2020 | November 24, 2020 |
| Atripla | Efavirenz, emtricitabine, tenofovir disoproxil fumarate | HIV | List with clinical criteria and/or conditions | Complete | October 30, 2007 | April 17, 2008 |
| Aubagio | Teriflunomide | Multiple sclerosis, relapsing-remitting | Do not list at the submitted price | Complete | August 28, 2013 | June 18, 2014 |
| Somatuline Autogel | Lanreotide acetate | Acromegaly | List in a similar manner to other drugs in class | Complete | February 20, 2007 | July 19, 2007 |
| Avodart | Dutasteride | Prostatic hyperplasia, benign | List in a similar manner to other drugs in class | Complete | August 24, 2004 | January 20, 2005 |
| Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | December 24, 2003 | May 27, 2004 |
| Azarga | Brinzolamide and timolol maleate suspension | Glaucoma and ocular hypertension | List in a similar manner to other drugs in class | Complete | August 28, 2009 | February 18, 2010 |
| Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | September 1, 2006 | March 28, 2007 |
| Azilect | Rasagiline mesylate | Parkinson?s disease | Complete | March 10, 2009 | ||
| Banzel | Rufinamide | Lennox-Gastaut syndrome | List with clinical criteria and/or conditions | Complete | September 20, 2011 | March 15, 2012 |
| Baqsimi | glucagon | Severe hypoglycemic reactions | Reimburse with clinical criteria and/or conditions | Complete | July 24, 2019 | January 22, 2020 |
| Baraclude | Entecavir | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | December 12, 2006 | November 28, 2007 |
| Basaglar | Insulin glargine | Diabetes mellitus, type 1; diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | October 5, 2015 | April 14, 2016 |
| Benlysta | Belimumab | systemic lupus erythematosus | Do not reimburse | Complete | May 29, 2019 | April 22, 2020 |
| Benlysta | Belimumab | Systemic lupus erythematosus | Do not list | Complete | September 19, 2011 | April 25, 2012 |
| Beovu | brolucizumab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | September 26, 2019 | May 21, 2020 |
| Biktarvy | bictegravir/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | April 30, 2018 | October 25, 2018 |
| Inflectra (Subsequent Entry Biologic) | Infliximab | Crohn’s disease and Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | April 12, 2016 | October 25, 2016 |
| Botox | OnabotulinumtoxinA | Urinary incontinence | List with criteria/condition | Complete | November 25, 2013 | November 12, 2014 |
| Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | November 2, 2018 | October 17, 2019 |
| Botox | OnabotulinumtoxinA | Neurogenic detrusor overactivity | List with clinical criteria and/or conditions | Complete | January 31, 2012 | July 19, 2012 |
| Botox | OnabotulinumtoxinA | Migraine | Do not list | Complete | August 15, 2013 | May 28, 2014 |
| Braftovi | encorafenib | Metastatic colorectal cancer | Active | December 16, 2020 | ||
| Ultibro Breezhaler | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | February 3, 2014 | December 19, 2014 |
| Enerzair Breezhaler | indacaterol glycopyrronium mometasone furoate | Asthma maintenance, adults | Reimburse with clinical criteria and/or conditions | Complete | May 19, 2020 | November 24, 2020 |
| Brenzys | Etanercept | Rheumatoid arthritis, Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | April 20, 2016 | October 25, 2016 |
| Breo Ellipta | fluticasone furoate/vilanterol | Asthma | Withdrawn | May 2, 2018 | ||
| Breo Ellipta | Fluticasone Furoate and Vilanterol (as trifenatate) | Asthma | List with clinical criteria and/or conditions | Complete | August 10, 2015 | February 18, 2016 |
| Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | June 28, 2017 | ||
| Breo Ellipta | Fluticasone furoate /vilanterol | Chronic Obstructive Pulmonary Disease (COPD) | List with criteria/condition | Complete | October 29, 2013 | August 18, 2014 |
| Brilinta | ticagrelor | Prevention of atherothrombotic events with history of myocardial infarction | Reimburse with clinical criteria and/or conditions | Complete | February 18, 2016 | August 25, 2016 |
| Brilinta | Ticagrelor | Acute coronary syndromes | Do not list | Complete | June 1, 2011 | December 16, 2011 |
| Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | June 8, 2010 | ||
| Brineura | cerliponase alfa | Neuronal Ceroid Lipofuscinosis Type 2 | Reimburse with clinical criteria and/or conditions | Complete | July 31, 2018 | May 23, 2019 |
| Brivlera | Brivaracetam | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | April 19, 2016 | January 25, 2017 |
| BuTrans | Buprenorphine transdermal patch | Pain, moderate intensity persistent pain | Do not list | Complete | May 9, 2011 | September 28, 2011 |
| BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | October 15, 2010 | ||
| Byetta | Exenatide | Diabetes mellitus, type 2 | Do not list | Complete | August 23, 2011 | July 19, 2012 |
| Bystolic | Nebivolol | Hypertension | Do not list at the submitted price | Complete | February 4, 2013 | July 18, 2013 |
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | September 13, 2019 | August 26, 2020 |
| Caduet | Amlodipine besylate/ atorvastatin calcium | Hypertension/ Dyslipidemia | List with clinical criteria and/or conditions | Complete | December 15, 2005 | May 17, 2006 |
| Campral | Acamprosate calcium | Alcohol Abstinence | Complete | July 22, 2008 | ||
| Campral | Acamprosate calcium | Alcohol Abstinence | List with clinical criteria and/or conditions | Complete | August 29, 2007 | March 27, 2008 |
| Cayston | Aztreonam for inhalation solution | Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections | List with clinical criteria and/or conditions | Complete | December 2, 2010 | July 18, 2011 |
| Celsentri | Maraviroc | HIV | Withdrawn | November 2, 2007 | ||
| Celsentri | Maraviroc | HIV | List with clinical criteria and/or conditions | Complete | May 7, 2008 | November 12, 2008 |
| Celsentri | Maraviroc | HIV infection | Do not list | Complete | December 8, 2010 | July 18, 2011 |
| Cerdelga | Eliglustat | Gaucher disease | Reimburse with clinical criteria and/or conditions | Complete | January 20, 2017 | July 26, 2017 |
| Champix | Varenicline tartrate | Smoking-cessation | List with clinical criteria and/or conditions | Complete | March 21, 2007 | August 16, 2007 |
| Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | September 3, 2009 | May 27, 2010 |
| Cimzia | Certolizumab pegol | Arthritis, psoriatic | List with criteria/condition | Complete | September 2, 2014 | April 17, 2015 |
| Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | May 13, 2019 | November 20, 2019 |
| Cimzia | Certolizumab pegol | Ankylosing spondylitis | List with criteria/condition | Complete | June 23, 2014 | April 17, 2015 |
| Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | October 24, 2018 | March 27, 2019 |
| Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | August 4, 2016 | March 22, 2017 |
| Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Do not list | Complete | June 8, 2006 | January 24, 2007 |
| Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Withdrawn | August 3, 2005 | ||
| Ciprodex | Ciprofloxacin hydrochloride & dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | List with clinical criteria and/or conditions | Complete | June 15, 2007 | October 18, 2007 |
| Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | June 11, 2004 | January 26, 2005 |
| Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | December 15, 2003 | May 27, 2004 |
| COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete | October 19, 2011 | April 19, 2012 |
| Constella | Linaclotide | Irritable bowel syndrome with constipation | Do not list | Complete | December 17, 2014 | September 23, 2015 |
| Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | May 1, 2019 | May 27, 2020 |
| Copaxone | Glatiramer acetate | Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis | Do not list | Complete | April 29, 2009 | November 25, 2009 |
| Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | May 24, 2016 | March 22, 2017 |
| Corzyna | ranolazine | Stable angina pectoris, adults | Active | August 17, 2020 | ||
| Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | February 19, 2016 | August 23, 2016 |
| Cosentyx | Secukinumab | Plaque psoriasis | List with criteria/condition | Complete | December 8, 2014 | October 28, 2015 |
| Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | February 19, 2016 | August 23, 2016 |
| Nucynta CR | Tapentadol | Pain, moderate to moderately severe | Do not list | Complete | February 1, 2011 | September 28, 2011 |
| Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete | November 2, 2018 | May 15, 2019 |
| Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | July 23, 2019 | May 27, 2020 |
| Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | March 6, 2008 | September 24, 2008 |
| Cuvposa | glycopyrrolate | chronic severe drooling, neurologic (pediatric) | Do not reimburse | Complete | May 31, 2019 | June 24, 2020 |
| Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | February 8, 2008 | August 14, 2008 |
| Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | February 8, 2008 | August 14, 2008 |
| Cystadrops | cysteamine | Corneal cystine crystal deposits | Reimburse with clinical criteria and/or conditions | Complete | December 10, 2018 | June 18, 2019 |
| Daklinza | daclatasvir | Hepatitis C, Chronic | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 19, 2016 |
| Daklinza | Daclatasvir | Hepatitis C, Chronic | List with clinical criteria and/or conditions | Complete | February 13, 2015 | September 21, 2015 |
| Daxas | Roflumilast | Chronic obstructive pulmonary disease | Do not list | Complete | November 30, 2010 | July 27, 2011 |
| Delstrigo | doravirine lamuvidine tenofovir disoproxil fumarate | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | November 16, 2018 | May 14, 2019 |
| Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete | September 20, 2006 | April 26, 2007 |
| Descovy | Emtricitabine /tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | January 29, 2016 | August 24, 2016 |
| Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | October 30, 2013 | October 16, 2014 |
| Dificid | Fidaxomicin | Clostridium difficile infection | Do not list at the submitted price | Complete | July 10, 2012 | December 19, 2012 |
| Dovato | dolutegravir / lamivudine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | February 21, 2019 | September 30, 2019 |
| Duaklir Genuair | Aclidinium bromide/formoterol fumarate dihydrate | Chronic obstructive pulmonary disease | List with clinical criteria and/or conditions | Complete | April 1, 2015 | September 18, 2015 |
| Duobrii | Halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | January 24, 2020 | October 28, 2020 |
| Duodopa | Levodopa / carbidopa (Drug Plan Submission) | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | February 8, 2018 | August 22, 2018 |
| Duodopa | Levodopa / carbidopa | Parkinson's disease | Do not list | Complete | December 19, 2008 | July 22, 2009 |
| DuoTrav | Travoprost and timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | March 24, 2006 | August 24, 2006 |
| Dupixent | dupilumab | atopic dermatitis | Do not reimburse | Complete | October 27, 2017 | June 27, 2018 |
| Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | October 22, 2019 | April 22, 2020 |
| Dupixent | dupilumab | Asthma | Active | November 26, 2020 | ||
| Dymista | Azelastine HCl and fluticasone propionate | Seasonal allergic rhinitis | Do not list | Complete | December 9, 2014 | June 17, 2015 |
| Dysport Therapeutic | abobotulinumtoxinA | lower limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | February 7, 2018 | August 23, 2018 |
| Dysport Therapeutic | abobotulinumtoxinA | Upper limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | April 24, 2017 | October 24, 2017 |
| Dysport Therapeutic | abobotulinumtoxinA | Cervical dystonia | Reimburse with clinical criteria and/or conditions | Complete | January 31, 2017 | July 26, 2017 |
| Ebixa | Memantine hydrochloride | Dementia (Alzheimer type), moderate to severe | Do not list | Complete | December 21, 2004 | November 23, 2005 |
| Edarbi | Azilsartan medoxomil | Hypertension | Do not list at the submitted price | Complete | March 8, 2013 | October 17, 2013 |
| Edarbyclor | Azilsartan medoxomil + chlorthalidone | Hypertension | Do not list | Complete | March 8, 2013 | October 17, 2013 |
| Edurant | Rilpivirine | HIV infection | List | Complete | July 29, 2011 | February 15, 2012 |
| Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | December 12, 2011 | June 14, 2012 |
| Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | May 5, 2010 | February 16, 2011 |
| Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | March 2, 2016 | August 24, 2016 |
| Elaprase | Idursulfase | Mucopolysarccharidosis II (MPS II), Hunter Syndrome | Do not list | Complete | July 13, 2007 | December 19, 2007 |
| Elelyso | Taliglucerase alfa | Gaucher disease | Do not list | Complete | August 15, 2014 | October 28, 2015 |
| Eliquis | Apixaban | Thromboembolic events prevention, (atrial fibrillation) | List with clinical criteria and/or conditions | Complete | September 25, 2012 | March 20, 2013 |
| Eliquis | Apixaban | Venous thromboembolic events, prevention | List with clinical criteria and/or conditions | Complete | December 20, 2011 | June 14, 2012 |
| Eliquis | Apixaban | Venous thromboembolic events, treatment and prevention of recurrence | List with clinical criteria and/or conditions | Complete | September 18, 2014 | May 7, 2015 |
| Trelegy Ellipta | fluticasone furoate umeclidinium vilanterol | Chronic obstructive pulmonary disease (COPD) | Reimburse with clinical criteria and/or conditions | Complete | March 1, 2018 | August 23, 2018 |
| Incruse Ellipta | Umeclidinium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | March 4, 2015 | September 18, 2015 |
| Emend | Aprepitant | Nausea and Vomiting, Chemotherapy induced | List with clinical criteria and/or conditions | Complete | August 29, 2007 | February 20, 2008 |
| Restasis ophthalmic emulsion | Cyclosporine | Dry eye disease | Do not list | Complete | December 17, 2010 | July 18, 2011 |
| Enablex | Darifenacin hydrobromide | Bladder, overactive | List with clinical criteria and/or conditions | Complete | October 1, 2008 | April 16, 2009 |
| Enablex | Darifenacin hydrobromide | Bladder, overactive | Do not list | Complete | April 26, 2006 | October 19, 2006 |
| Enspryng | satralizumab | Neuromyelitis optica spectrum disorder | Active | October 22, 2020 | ||
| Entresto | Sacubitril/valsartan | Heart failure, NYHA class II or III | List with clinical criteria and/or conditions | Complete | September 18, 2015 | March 18, 2016 |
| Entresto | sacubitril/valsartan | Heart failure, NYHA Class II or III | Active | May 22, 2020 | ||
| Entuzity KwikPen | human insulin | Diabetes mellitus | Active | January 27, 2021 | ||
| Entyvio | vedolizumab | Crohn’s disease | Active | July 23, 2020 | January 21, 2021 | |
| Entyvio | Vedolizumab | Ulcerative colitis | List with clinical criteria and/or conditions | Complete | February 20, 2015 | October 28, 2015 |
| Entyvio | Vedolizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | April 27, 2016 | October 31, 2016 |
| Entyvio | vedolizumab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | November 21, 2019 | May 19, 2020 |
| Epclusa | Sofosbuvir/ velpatasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | April 22, 2016 | October 26, 2016 |
| Erelzi | Etanercept | Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | February 2, 2017 | July 25, 2017 |
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | Do not list | Complete | October 5, 2012 | April 18, 2013 |
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | List with criteria/condition | Complete | August 29, 2014 | April 15, 2015 |
| Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | May 25, 2018 | March 27, 2019 |
| Evenity | romosozumab | Osteoporosis, postmenopausal women | Active | February 1, 2021 | ||
| Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | December 19, 2003 | June 23, 2004 |
| Exelon Patch | Rivastigmine | Dementia (Alzheimer's type) | Do not list | Complete | December 21, 2007 | July 23, 2008 |
| Exjade | Deferasirox | Iron overload | List with clinical criteria and/or conditions | Complete | October 26, 2006 | April 19, 2007 |
| Eylea | Aflibercept | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | September 16, 2014 | May 7, 2015 |
| Eylea | Aflibercept | Macular edema, central retinal vein occlusion | List with clinical criteria and/or conditions | Complete | October 17, 2014 | May 7, 2015 |
| Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | November 18, 2013 | October 20, 2014 |
| Eylea | Aflibercept | Macular edema, branch retinal vein occlusion | Reimburse with clinical criteria and/or conditions | Complete | December 14, 2015 | July 27, 2016 |
| Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | February 24, 2004 | November 24, 2004 |
| Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | December 10, 2004 | May 18, 2005 |
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete | April 16, 2012 | November 28, 2012 |
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | November 6, 2014 | ||
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | October 24, 2018 | March 27, 2019 |
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | February 23, 2018 | August 21, 2018 |
| Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | July 12, 2016 | February 21, 2017 |
| Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | September 24, 2015 | March 18, 2016 |
| Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | March 28, 2019 | July 24, 2019 |
| Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | June 21, 2017 | November 22, 2017 |
| Fibristal | Ulipristal acetate | Uterine fibroids | List with criteria/condition | Complete | April 17, 2013 | November 15, 2013 |
| Finacea | Azelaic acid | Rosacea | List | Complete | August 31, 2010 | February 16, 2011 |
| Firazyr | Icatibant | Hereditary angioedema | List with clinical criteria and/or conditions | Complete | March 4, 2014 | December 19, 2014 |
| Firazyr | icatibant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | |||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis (in women), Severe | Do not list | Complete | October 23, 2009 | March 17, 2010 |
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis, glucocorticoid induced | Do not list | Complete | December 18, 2008 | July 22, 2009 |
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Do not list | Complete | June 8, 2004 | December 22, 2004 |
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | May 29, 2006 | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | June 12, 2009 | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | December 18, 2008 | ||
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | Do not list | Complete | September 4, 2015 | April 27, 2016 |
| Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Active | March 31, 2020 | December 23, 2020 |
| Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | April 30, 2015 | November 20, 2015 |
| Fosavance | Alendronate sodium/cholecalciferol | Osteoporosis | Do not list | Complete | March 27, 2006 | September 27, 2006 |
| Fosrenol | Lanthanum carbonate hydrate | Hyperphosphatemia, end-stage renal disease | Do not list | Complete | June 28, 2007 | January 30, 2008 |
| Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | Complete | November 14, 2018 | ||
| Fycompa | Perampanel | Epilepsy, partial onset seizures | List with criteria/condition | Complete | March 8, 2013 | October 17, 2013 |
| Fycompa | Perampanel | Epilepsy, primary generalized tonic-clonic seizures | Reimburse with clinical criteria and/or conditions | Complete | November 24, 2015 | May 18, 2016 |
| Galafold | migalastat | Fabry Disease | Reimburse with clinical criteria and/or conditions | Complete | June 9, 2017 | January 24, 2018 |
| Galexos | Simeprevir | Hepatitis C, chronic | List with criteria/condition | Complete | August 22, 2013 | June 18, 2014 |
| Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | October 25, 2011 | May 24, 2012 |
| Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | May 27, 2013 | December 20, 2013 |
| Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | May 27, 2013 | December 20, 2013 |
| Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | May 27, 2013 | December 20, 2013 |
| Tudorza Genuair | Aclidinium bromide | Chronic Obstructive Pulmonary Disease | List with criteria/condition | Complete | August 21, 2013 | April 21, 2014 |
| Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | September 24, 2015 | March 18, 2016 |
| Gilenya | Fingolimod | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | May 10, 2011 | November 16, 2011 |
| Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Received | February 23, 2021 | ||
| Glatect | Glatiramer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) | Reimburse with clinical criteria and/or conditions | Complete | January 20, 2017 | July 25, 2017 |
| Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | September 30, 2013 | September 24, 2014 |
| Grastofil | Filgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | September 11, 2015 | March 18, 2016 |
| Harvoni | Ledipasvir / Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | September 15, 2014 | March 18, 2015 |
| Harvoni | ledipasvir, sofosbuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 18, 2016 |
| Hemangiol | Propranolol oral solution | Infantile hemangioma | Reimburse with clinical criteria and/or conditions | Complete | August 25, 2016 | February 21, 2017 |
| Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | December 23, 2014 | ||
| Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | June 30, 2020 | December 21, 2020 |
| Hepsera | Adefovir dipivoxil | Hepatitis B | List with clinical criteria and/or conditions | Complete | June 29, 2007 | October 18, 2007 |
| Hepsera | Adefovir dipivoxil | Hepatitis B | Do not list | Complete | April 24, 2006 | November 29, 2006 |
| Holkira Pak | ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 19, 2016 |
| Holkira Pak | Ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | December 3, 2014 | June 18, 2015 |
| Humira | Adalimumab | Crohn's disease | List with clinical criteria and/or conditions | Complete | July 12, 2007 | December 19, 2007 |
| Humira | Adalimumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | September 24, 2004 | February 11, 2005 |
| Humira | Adalimumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | February 4, 2013 | July 18, 2013 |
| Humira | Adalimumab | Ankylosing spondylitis (AS) | List with clinical criteria and/or conditions | Complete | November 17, 2006 | June 27, 2007 |
| Humira | Adalimumab | Ulcerative colitis | Do not list at the submitted price | Complete | September 25, 2015 | April 15, 2016 |
| Humira | Adalimumab | ulcerative colitis | Withdrawn | December 23, 2013 | ||
| Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | April 15, 2008 | October 16, 2008 |
| Humira | Adalimumab | Arthritis, Psoriatic | List with clinical criteria and/or conditions | Complete | June 21, 2006 | November 29, 2006 |
| Humira | Adalimumab | Hidradenitis suppurativa | Reimburse with clinical criteria and/or conditions | Complete | November 3, 2015 | May 19, 2016 |
| Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete | September 12, 2013 | July 17, 2014 |
| Stelara/Stelara I.V | ustekinumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | August 12, 2019 | July 16, 2020 |
| Stelara/Stelara I.V. | ustekinumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete | September 12, 2016 | March 21, 2017 |
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | May 15, 2017 | ||
| Ilaris | Canakinumab | Cryopyrin-Associated Periodic Syndrome | Do not list | Complete | July 7, 2010 | January 26, 2011 |
| Ilaris | Canakinumab | Systemic Juvenile Idiopathic Arthritis | Reimburse with clinical criteria and/or conditions | Complete | December 23, 2015 | June 17, 2016 |
| Ilumya | tildrakizumab | Psoriasis, moderate to severe plaque | Active | July 15, 2019 | ||
| Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn | December 21, 2017 | ||
| Iluvien | fluocinolone acetonide intravitreal implant | diabetic macular edema | Do not reimburse | Complete | April 3, 2019 | September 26, 2019 |
| Imbruvica | ibrutinib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | |||
| Imfinzi | durvalumab | Extensive-stage small cell lung cancer | Active | December 1, 2020 | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | August 23, 2011 | February 15, 2012 |
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | February 19, 2013 | June 13, 2013 |
| Incivek | Telaprevir | Hepatitis C, chronic | List with criteria/condition | Complete | December 21, 2012 | June 13, 2013 |
| Inflectra | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | List with criteria/condition | Complete | June 17, 2014 | December 19, 2014 |
| Inrebic | fedratinib | Myelofibrosis | Active | November 5, 2020 | ||
| Inspiolto Respimat | Tiotropium / olodaterol | List with criteria/condition | Complete | June 4, 2015 | December 17, 2015 | |
| Inspra | Eplerenone | Heart failure, NYHA class II | Do not list at the submitted price | Complete | July 12, 2013 | April 24, 2014 |
| Inspra | Eplerenone | Post myocardial infarction | Do not list | Complete | May 6, 2009 | November 25, 2009 |
| Intelence | Etravirine | HIV | List with clinical criteria and/or conditions | Complete | April 2, 2008 | August 14, 2008 |
| Intuniv XR | Guanfacine hydrochloride | Attention-deficit/hyperactivity disorder (ADHD) | Do not list | Complete | August 27, 2013 | September 24, 2014 |
| Invega | Paliperidone | Schizophrenia | Do not list | Complete | November 1, 2007 | May 28, 2008 |
| Invega Sustenna | Paliperidone palmitate | Schizophrenia | Do not list | Complete | July 9, 2010 | April 25, 2011 |
| Invokamet | Canagliflozin and metformin hydrochloride | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | March 3, 2016 | August 25, 2016 |
| Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | June 5, 2013 | ||
| Invokana | Canagliflozin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | February 24, 2014 | January 15, 2015 |
| Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | December 22, 2003 | June 23, 2004 |
| Isentress | Raltegravir | HIV | List with clinical criteria and/or conditions | Complete | November 29, 2007 | May 14, 2008 |
| Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | December 4, 2009 | June 23, 2010 |
| Izba | travoprost ophthalmic solution | Glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | March 1, 2017 | October 25, 2017 |
| Janumet | Sitagliptin phosphate monohydrate / metformin hydrochloride | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | November 4, 2009 | June 23, 2010 |
| Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | Do not list | Complete | December 20, 2007 | June 18, 2008 |
| Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | October 29, 2009 | June 23, 2010 |
| Jardiance | Empagliflozin | Diabetes mellitus, type 2 with high cardiovascular risk | Reimburse with clinical criteria and/or conditions | Complete | April 27, 2016 | October 26, 2016 |
| Jardiance | Empagliflozin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | April 23, 2015 | October 15, 2015 |
| Jentadueto | Linagliptin-metformin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | March 8, 2013 | October 17, 2013 |
| Jetrea | Ocriplasmin | Vitreomacular adhesion | List with criteria/condition | Complete | June 6, 2013 | December 20, 2013 |
| Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | May 29, 2015 | February 24, 2016 |
| Jorveza | budesonide | Eosinophilic esophagitis, adults | Reimburse with clinical criteria and/or conditions | Complete | November 8, 2019 | October 28, 2020 |
| Jorveza | budesonide | Maintenance of Eosinophilic esophagitis in adults | Active | November 5, 2020 | ||
| Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete | August 2, 2018 | May 23, 2019 |
| Juluca | Dolutegravir rilpivirine | HIV infection | Reimburse with clinical criteria and/or conditions | Complete | December 21, 2017 | June 20, 2018 |
| Jurnista | Hydromorphone hydrochloride | Pain, Chronic (moderate to severe) | Do not list | Complete | December 4, 2009 | May 19, 2010 |
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete | July 8, 2014 | April 17, 2015 |
| Kalydeco | Ivacaftor | Cystic Fibrosis, CFTR gating mutations | List with criteria/condition | Complete | May 1, 2014 | December 19, 2014 |
| Kalydeco | Ivacaftor | Cystic fibrosis, R117H CFTR gating mutation | List with criteria/condition | Complete | May 8, 2015 | November 19, 2015 |
| Kalydeco | Ivacaftor | Cystic fibrosis, G551D mutation | List with criteria/condition | Complete | September 27, 2012 | March 22, 2013 |
| Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | November 2, 2017 | September 26, 2018 |
| Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | January 30, 2014 | January 15, 2015 |
| Kesimpta | ofatumumab | Multiple Sclerosis, relapsing | Active | August 25, 2020 | ||
| Kevzara | sarilumab | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | October 12, 2016 | April 18, 2017 |
| Keytruda | pembrolizumab | Colorectal cancer | Active | November 30, 2020 | ||
| Keytruda | pembrolizumab | Classical Hodgkin lymphoma | Received | January 29, 2021 | ||
| Kineret | anakinra | Still's disease | Active | December 21, 2020 | ||
| Kivexa | Abacavir/lamivudine | HIV infection | List in a similar manner to other drugs in class | Complete | July 26, 2005 | December 7, 2005 |
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | June 6, 2013 | ||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, type 2 | List with criteria/condition | Complete | August 23, 2013 | June 20, 2014 |
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Reimburse with clinical criteria and/or conditions | Complete | February 1, 2016 | October 26, 2016 |
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Do not list | Complete | July 8, 2010 | January 26, 2011 |
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria | Complete | June 1, 2011 | ||
| Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Active | June 25, 2020 | February 24, 2021 |
| Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | February 25, 2019 | ||
| Lancora | Ivabradine | Heart failure, NYHA class II or III | Reimburse with clinical criteria and/or conditions | Complete | November 8, 2016 | May 24, 2017 |
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Complete | June 9, 2009 | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | February 11, 2005 | September 28, 2005 |
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | March 27, 2006 | October 25, 2006 |
| Lapelga | Pegfilgrastim | Febrile neutropenia | Complete | February 23, 2018 | ||
| Latuda | Lurasidone | Schizophrenia | Do not list | Complete | July 3, 2012 | January 23, 2013 |
| Latuda | Lurasidone | Schizophrenia | List with criteria/condition | Complete | May 9, 2013 | December 20, 2013 |
| Latuda | lurasidone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | |||
| Ledaga | chlormethine hydrochloride | T-cell lymphoma | Active | December 21, 2020 | ||
| Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | November 27, 2014 | June 18, 2015 |
| Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | October 1, 2013 | ||
| Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | December 19, 2005 | August 2, 2006 |
| Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | March 10, 2009 | August 20, 2009 |
| Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | February 2, 2009 | ||
| Levemir | Insulin detemir | Diabetes mellitus Type1, Pediatrics | Do not list | Complete | March 10, 2009 | August 20, 2009 |
| pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Active | July 17, 2020 | February 3, 2021 |
| Lixiana VTE | Edoxaban | Venous thromboembolism, treatment and recurrence prevention. | Reimburse with clinical criteria and/or conditions | Complete | September 9, 2016 | May 25, 2017 |
| Lixiana NVAF | Edoxaban | Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. | Reimburse with clinical criteria and/or conditions | Complete | September 9, 2016 | March 21, 2017 |
| Lodalis | Colesevelam hydrochloride | Hypercholesterolemia | Do not list at the submitted price | Complete | April 27, 2012 | December 19, 2012 |
| Lokelma | sodium zirconium cyclosilicate | Hyperkalemia, adults | Do not reimburse | Complete | May 17, 2019 | March 25, 2020 |
| Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete | December 2, 2009 | May 19, 2010 |
| Lucentis | Ranibizumab injection | Macular edema, secondary to retinal vein occlusion | List with clinical criteria and/or conditions | Complete | April 25, 2012 | October 18, 2012 |
| Lucentis | Ranibizumab | Macular degeneration, age-related | List with clinical criteria and/or conditions | Complete | July 12, 2007 | March 27, 2008 |
| Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | February 28, 2014 | February 19, 2015 |
| Lucentis | Ranibizumab | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | September 14, 2011 | March 19, 2012 |
| Luxturna | voretigene neparvovec | Vision loss, inherited retinal dystrophy | Reimburse with clinical criteria and/or conditions | Complete | April 23, 2020 | November 12, 2020 |
| Lyrica | Pregabalin | diabetic peripheral neuropathy | Do not list | Complete | March 20, 2009 | September 23, 2009 |
| Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | June 27, 2005 | January 25, 2006 |
| Pantoloc M | Pantoprazole magnesium | Gastric acid secretion, reduction of | List in a similar manner to other drugs in class | Complete | March 17, 2006 | July 20, 2006 |
| Macugen | Pegaptanib sodium | Macular degeneration, age-related | Do not list | Complete | October 20, 2005 | May 25, 2006 |
| Mavenclad | cladribine | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | December 1, 2017 | October 24, 2018 |
| Maviret | glecaprevir pibrentasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | June 9, 2017 | January 23, 2018 |
| Mayzent | siponimod | Secondary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | September 26, 2019 | July 21, 2020 |
| MDK-Nitisinone | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | September 29, 2017 | April 25, 2018 |
| Mictoryl | Propiverine hydrochloride | Overactive bladder (OAB) | Reimburse with clinical criteria and/or conditions | Complete | October 14, 2016 | April 19, 2017 |
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | February 12, 2016 | ||
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Reimburse | Complete | October 7, 2016 | April 18, 2017 |
| Monoferric | Iron (III) Isomaltoside 1000 | iron deficiency anemia | Reimburse with clinical criteria and/or conditions | Complete | June 26, 2019 | March 25, 2020 |
| Monoprost | latanoprost | glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | October 25, 2017 | April 24, 2018 |
| Movapo | apomorphine hydrochloride | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | July 6, 2017 | January 23, 2018 |
| Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete | January 24, 2012 | September 26, 2012 |
| Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | September 18, 2009 | May 27, 2010 |
| Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | March 3, 2005 | July 8, 2005 |
| Myozyme | Alglucosidase | Pompe's disease | List with clinical criteria and/or conditions | Complete | October 10, 2006 | June 14, 2007 |
| Myrbetriq | Mirabegron | Overactive bladder | List with criteria/condition | Complete | November 27, 2013 | November 12, 2014 |
| Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | March 8, 2013 | ||
| Naglazyme | Galsulfase (Drug Plan Submission) | Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) | List with clinical criteria and/or conditions | Complete | August 20, 2015 | February 19, 2016 |
| Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | January 30, 2014 | January 15, 2015 |
| Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | March 29, 2004 | October 27, 2004 |
| Neupro | Rotigotine | Parkinson's disease | Do not list | Complete | July 31, 2013 | May 28, 2014 |
| Neupro | Rotigotine | Parkinson’s disease | List with clinical criteria and/or conditions | Complete | May 21, 2015 | November 19, 2015 |
| Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | July 31, 2006 | February 28, 2007 |
| Nexplanon | etonogestrel | Prevention of pregnancy | Reimburse with clinical criteria and/or conditions | Complete | June 3, 2020 | October 20, 2020 |
| Nitisinone | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | January 25, 2018 | August 23, 2018 |
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | List with clinical criteria and/or conditions | Complete | November 23, 2005 | May 17, 2006 |
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | December 16, 2004 | September 28, 2005 |
| Nplate | Romiplostim | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) | Do not list | Complete | September 29, 2009 | May 27, 2010 |
| Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | October 24, 2018 | March 27, 2019 |
| Nucala | Mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | December 18, 2015 | June 16, 2016 |
| Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete | April 17, 2018 | October 23, 2018 |
| NuvaRing | Etonogestrel/ethinyl estradiol | Contraceptive, ring | List with clinical criteria and/or conditions | Complete | May 5, 2006 | November 29, 2006 |
| Ocaliva | Obeticholic Acid | Primary Biliary Cholangitis | Reimburse with clinical criteria and/or conditions | Complete | December 22, 2016 | July 25, 2017 |
| Ocrevus | ocrelizumab | multiple sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | May 16, 2017 | November 21, 2017 |
| Ocrevus | ocrelizumab | Primary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | October 26, 2017 | April 26, 2018 |
| Odefsey | emtricitabine/rilpivirine/ tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | November 24, 2016 | May 25, 2017 |
| Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Active | July 24, 2020 | February 24, 2021 |
| Ofev | Nintedanib | Idiopathic pulmonary fibrosis | List with clinical criteria and/or conditions | Complete | April 23, 2015 | October 15, 2015 |
| Olmetec | Olmesartan medoxomil | Hypertension | List in a similar manner to other drugs in class | Complete | November 28, 2008 | May 27, 2009 |
| Olmetec Plus | Olmesartan medoxomil + hydrochlorothiazide | Hypertension | List in a similar manner to other drugs in class | Complete | November 28, 2008 | May 27, 2009 |
| Olumiant | baricitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | December 20, 2018 | August 2, 2019 |
| Omnaris | Ciclesonide nasal spray | Allergic Rhinitis (seasonal and perennial) | Do not list | Complete | May 7, 2008 | November 12, 2008 |
| Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | Complete | June 12, 2009 | ||
| Onbrez | Indacaterol | Chronic obstructive pulmonary disease | List in a similar manner | Complete | February 29, 2012 | August 16, 2012 |
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | May 9, 2013 | November 15, 2013 |
| Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | November 9, 2009 | June 17, 2010 |
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | Withdrawn | May 28, 2012 | ||
| Onpattro | patisiran | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | January 25, 2019 | July 25, 2019 |
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | May 10, 2011 | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | August 22, 2011 | February 15, 2012 |
| Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete | May 29, 2019 | March 25, 2020 |
| Onureg | azacitidine | Acute myeloid leukemia | Pending | |||
| Opdivo-Yervoy | nivolumab-ipilimumab | Malignant Pleural Mesothelioma (MPM) | Active | October 29, 2020 | ||
| Opsumit | Macitentan | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete | December 18, 2015 | January 28, 2015 |
| Oralair | Grass Pollen Allergen Extract | Allergic rhinitis | List with criteria/condition | Complete | September 21, 2012 | March 20, 2013 |
| Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | October 26, 2006 | June 27, 2007 |
| Orencia | Abatacept | Arthritis, rheumatoid | List with clinical criteria and/or conditions | Complete | November 29, 2012 | July 18, 2013 |
| Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | December 2, 2009 | June 17, 2010 |
| Orencia | Abatacept | Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid | List with clinical criteria and/or conditions | Complete | August 29, 2008 | April 22, 2009 |
| Orfadin | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | August 29, 2017 | February 21, 2018 |
| Orilissa | elagolix | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | |||
| Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation | Do not reimburse | Complete | January 28, 2016 | October 26, 2016 |
| Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older | Do not reimburse | Complete | February 22, 2018 | September 26, 2018 |
| Otezla | Apremilast | Plaque psoriasis | Do not list | Complete | October 8, 2014 | July 22, 2015 |
| Otezla | Apremilast | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | March 3, 2016 | October 26, 2016 |
| Otezla | Apremilast | Arthritis, psoriatic | List with criteria/condition | Complete | June 8, 2015 | December 17, 2015 |
| Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | January 25, 2018 | October 24, 2018 |
| Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | November 23, 2018 | May 15, 2019 |
| Ozurdex | dexamethasone | Diabetic macular edema | Do not reimburse | Complete | September 26, 2017 | October 24, 2018 |
| Ozurdex | Dexamethasone intravitreal implant | Macular edema, central retinal vein occlusion | Do not list | Complete | September 1, 2011 | April 25, 2012 |
| Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete | May 14, 2004 | October 14, 2004 |
| Perseris | risperidone | Schizophrenia, adults | Active | January 29, 2021 | ||
| Pheburane | Sodium phenylbutyrate | Urea cycle disorders | List | Complete | October 20, 2015 | April 15, 2016 |
| Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | May 9, 2013 | January 22, 2014 |
| Picato | Ingenol mebutate | Actinic keratosis | Complete | May 26, 2014 | ||
| Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | November 16, 2018 | May 14, 2019 |
| Plegridy | Peginterferon beta-1a | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | June 26, 2015 | December 17, 2015 |
| Teveten Plus | Eprosartan mesylate/ hydrochlorothiazide | Hypertension, Essential | List in a similar manner to other drugs in class | Complete | July 8, 2004 | December 15, 2004 |
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | March 18, 2013 | July 18, 2013 |
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | October 28, 2010 | June 22, 2011 |
| Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete | July 8, 2008 | January 28, 2009 |
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | May 31, 2010 | ||
| Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | January 12, 2016 | July 20, 2016 |
| Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | May 30, 2016 | ||
| Prevymis | letermovir | Cytomegalovirus infection, prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | December 7, 2017 | June 20, 2018 |
| Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete | December 15, 2006 | July 25, 2007 |
| Prezcobix | Darunavir/cobicistat | HIV Infection | List with criteria/condition | Complete | May 22, 2014 | March 18, 2015 |
| Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | August 29, 2006 | February 14, 2007 |
| Prezista | Darunavir | HIV (treatment naive) | List with clinical criteria and/or conditions | Complete | March 27, 2009 | October 14, 2009 |
| Prezista | Darunavir | HIV infection (Pediatric) | List with clinical criteria and/or conditions | Complete | December 22, 2009 | June 17, 2010 |
| Pristiq | Desvenlafaxine succinate | Depressive, Major Disorder (MDD) | Do not list | Complete | March 5, 2009 | September 23, 2009 |
| Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete | December 21, 2017 | August 22, 2018 |
| Procysbi | cysteamine bitartrate | Nephropathic cystinosis | Reimburse with clinical criteria and/or conditions | Complete | August 8, 2017 | January 24, 2018 |
| Prolia | Denosumab | Osteoporosis, postmenopausal women | List with clinical criteria and/or conditions | Complete | August 26, 2010 | March 30, 2011 |
| Prolia | Denosumab | Osteoporosis | Reimburse with clinical criteria and/or conditions | Complete | October 26, 2015 | May 20, 2016 |
| Prolia | Denosumab (Drug Plan Submission) | Osteoporosis, men | List with clinical criteria and/or conditions | Complete | March 10, 2015 | September 21, 2015 |
| Quinsair | Levofloxacin | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections | Reimburse with clinical criteria and/or conditions | Complete | May 31, 2016 | November 21, 2016 |
| Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | July 5, 2018 | March 27, 2019 |
| Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | October 29, 2007 | June 25, 2008 |
| RAPAFLO | Silodosin | Benign prostatic hyperplasia | Do not list | Complete | October 25, 2011 | April 19, 2012 |
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | October 25, 2005 | August 24, 2006 |
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | Complete | June 19, 2007 | ||
| Rasilez | Aliskiren | Hypertension | Do not list | Complete | November 30, 2007 | June 25, 2008 |
| Ravicti | glycerol phenylbutyrate | Urea cycle disorders | Reimburse with clinical criteria and/or conditions | Complete | August 30, 2016 | March 21, 2017 |
| Rebif | Interferon beta-1a | Clinically isolated syndrome | Do not list | Complete | March 8, 2013 | August 15, 2013 |
| Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Received | January 28, 2021 | ||
| Reblozyl | luspatercept | beta-thalassemia associated anemia | Active | November 26, 2020 | ||
| Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete | May 7, 2008 | January 28, 2009 |
| Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete | September 21, 2004 | March 23, 2005 |
| Remicade | Infliximab | Ulcerative Colitis | Do not list | Complete | September 29, 2008 | April 22, 2009 |
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | February 24, 2006 | July 20, 2006 |
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | Do not list | Complete | July 14, 2004 | November 17, 2004 |
| Remsima | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | Withdrawn | May 30, 2014 | ||
| Remsima | infliximab | Rheumatoid arthritis | Active | September 24, 2020 | ||
| Renflexis | infliximab | rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete | September 5, 2017 | February 20, 2018 |
| Repatha | Evolocumab | Primary hyperlipidemia; mixed dyslipidemia | List with clinical criteria and/or conditions | Complete | June 30, 2015 | February 19, 2016 |
| Repatha | Evolocumab | Primary hyperlipidemia and mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | February 17, 2017 | November 22, 2017 |
| Replagal | Agalsidase alfa | Fabry Disease | Do not list | Complete | February 19, 2004 | November 24, 2004 |
| Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | January 30, 2012 | July 19, 2012 |
| Spiriva Respimat | Tiotropium bromide | Chronic obstructive pulmonary disease | List with clinical criteria and/or conditions | Complete | December 23, 2014 | July 16, 2015 |
| Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | September 20, 2006 | February 14, 2007 |
| Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | May 29, 2019 | November 19, 2019 |
| Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | November 26, 2015 | July 27, 2016 |
| Revolade | Eltrombopag olamine | Chronic immune thrombocytopenic purpura | Do not list | Complete | April 26, 2011 | October 24, 2011 |
| Revolade | eltrombopag | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | |||
| Revolade | Eltrombopag | Thrombocytopenia associated with chronic hepatitis c infection | List with criteria/condition | Complete | March 31, 2014 | March 18, 2015 |
| Rexulti | Brexpiprazole | schizophrenia | Reimburse with clinical criteria and/or conditions | Complete | February 3, 2017 | November 22, 2017 |
| Reyataz | Atazanavir | HIV infection | List in a similar manner to other drugs in class | Complete | December 16, 2003 | May 27, 2004 |
| Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | July 4, 2019 | February 4, 2020 |
| Rinvoq | upadacitinib | Psoriatic Arthritis, Adults. | Active | January 4, 2021 | ||
| Rituxan | Rituximab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | June 26, 2006 | February 14, 2007 |
| Rituxan | Rituximab | Granulomatosis with polyangiitis and microscopic polyangiitis | List with clinical criteria and/or conditions | Complete | February 24, 2012 | August 16, 2012 |
| Rosiver | Ivermectin | Rosacea | List with criteria/condition | Complete | April 30, 2015 | November 19, 2015 |
| Ruzurgi | amifampridine | Lambert-Eaton myasthenic syndrome | Active | October 5, 2020 | ||
| Rybelsus | semaglutide | diabetes mellitus, type 2 | Active | November 26, 2020 | ||
| Samsca | Tolvaptan | Hyponatremia, non-hypovolemic | Do not list | Complete | July 3, 2012 | February 13, 2013 |
| Saphris | Asenapine | Schizophrenia | Do not list | Complete | December 12, 2011 | June 14, 2012 |
| Saphris | Asenapine | Bipolar I disorder | List with clinical criteria and/or conditions | Complete | December 12, 2011 | June 14, 2012 |
| Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, Neuropathic (adjunctive) in MS. | Do not list | Complete | February 27, 2007 | September 26, 2007 |
| Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) | Do not list | Complete | August 7, 2007 | February 20, 2008 |
| Saxenda | liraglutide | Chronic weight management in adults | Active | December 23, 2020 | ||
| Sebivo | Telbivudine | Hepatitis B (chronic) | Do not list | Complete | December 4, 2006 | September 26, 2007 |
| Seebri | Glycopyrronium bromide | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | November 30, 2012 | May 15, 2013 |
| Segluromet | ertugliflozin and metformin hydrochloride | Diabetes mellitus, Type 2 | Do not reimburse | Complete | April 30, 2018 | January 23, 2019 |
| Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | November 14, 2018 | ||
| Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | August 20, 2004 | March 23, 2005 |
| Signifor | Pasireotide diaspartate | Cushing’s disease | Do not list | Complete | February 27, 2014 | February 24, 2015 |
| Siliq | brodalumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | December 14, 2017 | June 20, 2018 |
| Silkis | Calcitriol | Psoriasis, mild to moderate plaque | Do not list | Complete | March 15, 2010 | September 22, 2010 |
| Simbrinza | Brinzolamide / brimonidine | Glaucoma and ocular hypertension | List | Complete | November 3, 2014 | June 17, 2015 |
| Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | September 3, 2009 | March 17, 2010 |
| Simponi | Golimumab | Ankylosing spondylitis | List in a similar manner | Complete | September 3, 2009 | March 17, 2010 |
| Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete | July 12, 2013 | March 19, 2014 |
| Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | September 3, 2009 | March 17, 2010 |
| Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | January 16, 2015 | ||
| Skyrizi | risankizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | October 22, 2018 | May 28, 2019 |
| Soliqua | lixisenatide + insulin glargine | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | May 18, 2018 | December 24, 2018 |
| Soliris | Eculizumab | Paroxysmal nocturnal hemoglobinuria (PNH) | Do not list | Complete | September 18, 2009 | February 18, 2010 |
| Soliris | Eculizumab | Atypical hemolytic uremic syndrome | Complete | February 9, 2015 | ||
| Soliris | eculizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | February 25, 2020 | August 19, 2020 |
| Soliris | eculizumab | Myasthenia Gravis (gMG), adults | Reimburse with clinical criteria and/or conditions | Complete | April 1, 2020 | October 19, 2020 |
| Soliris | Eculizumab | Hemolytic Uremic Syndrome, Atypical | Do not list | Complete | January 7, 2013 | July 18, 2013 |
| Somavert | Pegvisomant | acromegaly | Do not list | Complete | January 25, 2006 | August 2, 2006 |
| Sovaldi | Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | October 1, 2013 | August 18, 2014 |
| Sovaldi | sofosbuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | January 6, 2016 | May 18, 2016 |
| Spinraza | nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | June 28, 2017 | December 22, 2017 |
| Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | July 24, 2018 | February 27, 2019 |
| Spravato | esketamine hydrochloride | Major depressive disorder (MDD), adults | Do not reimburse | Active | June 24, 2019 | December 16, 2020 |
| Spriafil | Posaconazole | Aspergillus and Candida infections | Do not list | Complete | May 24, 2007 | January 30, 2008 |
| Stalevo | Carbidopa, levodopa and entacapone | Parkinsons Disease | List in a similar manner | Complete | April 15, 2008 | October 16, 2008 |
| Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete | April 30, 2018 | January 23, 2019 |
| Stelara | Ustekinumab | Psoriasis | List with clinical criteria and/or conditions | Complete | January 7, 2009 | June 17, 2009 |
| Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete | October 30, 2013 | October 20, 2014 |
| Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | Do not list | Complete | January 25, 2005 | September 28, 2005 |
| Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | Complete | September 25, 2006 | ||
| Strensiq | Asfotase alfa | Hypophosphatasia, pediatric-onset | List with criteria/condition | Complete | August 21, 2015 | March 23, 2016 |
| Stribild | Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate | HIV infection | List with criteria/condition | Complete | November 30, 2012 | May 15, 2013 |
| Sublinox | Zolpidem tartrate | Insomnia | Do not list | Complete | March 7, 2013 | September 25, 2013 |
| Sublocade | buprenorphine | Opioid use disorder, treatment | Reimburse with clinical criteria and/or conditions | Complete | December 20, 2018 | June 19, 2019 |
| Suboxone | Buprenorphine/naloxone | Opioid drug dependence (Substitution treatment) | List with clinical criteria and/or conditions | Complete | March 6, 2008 | September 24, 2008 |
| Sunvepra | Asunaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | February 13, 2015 | July 20, 2016 |
| Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete | July 20, 2006 | March 28, 2007 |
| Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | September 20, 2006 | April 26, 2007 |
| Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | |||
| Symtuza | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | December 22, 2017 | July 25, 2018 |
| Synjardy | Empagliflozin and metformin | Diabetes mellitus (Type 2) | Reimburse with clinical criteria and/or conditions | Complete | April 29, 2016 | October 25, 2016 |
| Tagrisso | osimertinib | Non-small cell lung cancer | Pending | |||
| Takhzyro | lanadelumab | Hereditary angioedema, prevention | Reimburse with clinical criteria and/or conditions | Complete | May 29, 2019 | November 19, 2019 |
| Taltz | ixekizumab | Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | September 20, 2019 | March 24, 2020 |
| Taltz | ixekizumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | February 20, 2018 | August 21, 2018 |
| Taltz | Ixekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | March 23, 2016 | October 25, 2016 |
| Talzenna | talazoparib | Breast cancer | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Tarceva | Erlotinib | Cancer, Lung , non-small cell | List with clinical criteria and/or conditions | Complete | July 19, 2005 | December 7, 2005 |
| Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | November 30, 2010 | ||
| Targin | Oxycodone HCI / naloxone HCI | Pain, moderate to severe and relief of opioid-induced constipation | Do not list | Complete | July 5, 2011 | January 25, 2012 |
| TBC | Darunavir / cobicistat | HIV infection | Withdrawn | April 4, 2014 | ||
| TBC | idecabtagene vicleucel | Multiple myeloma | Active | December 16, 2020 | ||
| TBC | brexucabtagene autoleucel | Mantle cell lymphoma | Active | December 18, 2020 | ||
| TBC | triheptanoin | Long-chain fatty acid oxidation disorders | Pending | |||
| TBC | risdiplam | Spinal muscular atrophy | Active | November 19, 2020 | ||
| TBC | budesonide/ glycopyrronium /formoterol fumarate | chronic obstructive pulmonary disease (COPD) | Active | January 28, 2021 | ||
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | August 4, 2020 | ||
| TBC | inclisiran | Primary hypercholesterolemia | Pending | |||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | September 26, 2019 | ||
| TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | November 1, 2018 | ||
| TBC | filgrastim | Cancelled | ||||
| TBC | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation | Active | January 22, 2021 | ||
| TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | February 4, 2019 | ||
| TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | July 4, 2019 | ||
| Tecfidera | Dimethyl fumarate | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | February 4, 2013 | September 25, 2013 |
| Technivie | Ombitasvir/ paritaprevir/ ritonavir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | September 4, 2015 | March 18, 2016 |
| Tegsedi | inotersen | hereditary transthyretin amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | February 22, 2019 | December 18, 2019 |
| Telzir | Fosamprenavir calcium | HIV infection | List in a similar manner to other drugs in class | Complete | January 24, 2005 | June 16, 2005 |
| Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | May 5, 2008 | January 28, 2009 |
| Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | June 22, 2007 | January 30, 2008 |
| Tivicay | Dolutegravir | HIV infection | List | Complete | October 18, 2013 | August 18, 2014 |
| Toctino | Alitretinoin | Eczema | List with clinical criteria and/or conditions | Complete | May 6, 2011 | October 24, 2011 |
| Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | April 27, 2012 | October 18, 2012 |
| Trajenta | Linagliptin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | August 23, 2011 | February 15, 2012 |
| Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | October 2, 2006 | May 17, 2007 |
| Translarna | ataluren | Cancelled | ||||
| Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete | February 27, 2006 | July 20, 2006 |
| Tremfya | guselkumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | August 25, 2017 | February 21, 2018 |
| Tresiba | insulin degludec | Diabetes mellitus, Type 1 & 2 | Reimburse with clinical criteria and/or conditions | Complete | May 31, 2017 | November 20, 2017 |
| Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | November 29, 2007 | April 17, 2008 |
| Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | May 1, 2019 | February 12, 2020 |
| Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn | October 31, 2014 | ||
| Triumeq | Dolutegravir / abacavir / lamivudine | HIV Infection | List with criteria/condition | Complete | July 31, 2014 | April 17, 2015 |
| Trosec | Trospium chloride | Bladder, overactive | List with clinical criteria and/or conditions | Complete | March 24, 2006 | August 24, 2006 |
| Trulicity | Dulaglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | December 22, 2015 | June 16, 2016 |
| Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | May 29, 2006 | October 25, 2006 |
| Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | July 7, 2008 | December 17, 2008 |
| Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV-1 infection, pre-exposure prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | March 3, 2016 | August 24, 2016 |
| Tukysa | tucatinib | Advanced or Metastatic Breast Cancer | Pending | |||
| Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | August 23, 2011 | December 16, 2011 |
| Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | July 9, 2010 | ||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | May 6, 2008 | February 25, 2009 |
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | October 26, 2006 | April 26, 2007 |
| Uloric | Febuxostat | Gout | List with clinical criteria and/or conditions | Complete | October 27, 2010 | April 25, 2011 |
| Unituxin | dinutuximab | Neuroblastoma | Active | November 23, 2020 | ||
| Uptravi | Selexipag | Pulmonary arterial hypertension (WHO class II and III) | Reimburse with clinical criteria and/or conditions | Complete | March 31, 2016 | October 28, 2016 |
| Vantas | Histrelin acetate | Cancer, prostate | Do not list | Complete | September 20, 2006 | April 26, 2007 |
| Vascepa | icosapent ethyl | Ischemic events in statin-treated patients | Reimburse with clinical criteria and/or conditions | Complete | June 17, 2019 | July 16, 2020 |
| Velphoro | sucroferric oxyhydroxide | Hyperphosphatemia, end-stage renal disease | Reimburse with clinical criteria and/or conditions | Complete | June 12, 2018 | January 2, 2019 |
| Veltassa | patiromer | Hyperkalemia, adults (chronic kidney disease) | Active | October 30, 2020 | ||
| Vemlidy | tenofovir alafenamide | Hepatitis B, chronic | Reimburse with clinical criteria and/or conditions | Complete | September 28, 2017 | March 26, 2018 |
| Venclexta | venetoclax | Acute myeloid leukemia | Active | January 8, 2021 | ||
| Venclexta | venetoclax | Acute myeloid leukemia | Active | January 22, 2021 | ||
| Verkazia | cyclosporine | Severe vernal keratoconjunctivitis, pediatric (≥4 years) | Reimburse with clinical criteria and/or conditions | Complete | May 22, 2019 | November 18, 2019 |
| Vesicare | Solifenacin succinate | Bladder, overactive | List with clinical criteria and/or conditions | Complete | January 5, 2009 | June 17, 2009 |
| Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | July 24, 2006 | January 24, 2007 |
| VesiFlow | Solifenacin succinate / tamsulosin hydrochloride | Benign prostatic hyperplasia | Withdrawn | April 6, 2015 | ||
| VFEND | Voriconazole | Aspergillosis, Invasive | List with clinical criteria and/or conditions | Complete | October 25, 2004 | April 14, 2005 |
| VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | March 24, 2006 | October 25, 2006 |
| VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | August 24, 2004 | ||
| Viacoram | perindopril arginine / amlodipine | Hypertension, essential | Reimburse with clinical criteria and/or conditions | Complete | May 2, 2016 | October 26, 2016 |
| Viberzi | eluxadoline | Irritable bowel syndrome with diarrhea | Do not reimburse | Complete | February 23, 2018 | August 24, 2018 |
| Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | October 20, 2016 | ||
| Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete | November 29, 2010 | September 28, 2011 |
| Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | December 21, 2012 | June 13, 2013 |
| Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | February 19, 2013 | June 13, 2013 |
| Victrelis | Boceprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | May 3, 2011 | October 24, 2011 |
| Viibryd | vilazodone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | |||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete | August 5, 2014 | March 25, 2015 |
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Reimburse with clinical criteria and/or conditions | Complete | November 10, 2015 | May 20, 2016 |
| Vimpat | Lacosamide | Epilepsy, partial onset seizures | List with clinical criteria and/or conditions | Complete | October 25, 2010 | April 25, 2011 |
| Viread | Tenofovir disoproxil fumarate | HIV infection | Complete | July 7, 2008 | ||
| Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | October 2, 2008 | March 18, 2009 |
| Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | February 23, 2004 | August 25, 2004 |
| Viread | Tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | August 11, 2005 | March 15, 2006 |
| Visanne | Dienogest | Pain, pelvic pain associated with endometriosis | List with clinical criteria and/or conditions | Complete | October 18, 2011 | April 19, 2012 |
| Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Active | November 16, 2020 | ||
| Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete | July 9, 2008 | December 17, 2008 |
| Vonvendi | von Willebrand Factor [recombinant] | von Willebrand disease, adults, treatment and perioperative management | Active | April 29, 2020 | ||
| Vosevi | sofosbuvir velpatasvir voxilaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | July 28, 2017 | January 23, 2018 |
| VPRIV | Velaglucerase alfa | Gaucher Disease | List with clinical criteria and/or conditions | Complete | October 28, 2010 | April 25, 2011 |
| Vyndaqel | tafamidis | transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | July 4, 2019 | February 19, 2020 |
| Vyvanse | Lisdexamfetamine dimesylate | Attention deficit hyperactivity disorder | Do not list | Complete | July 10, 2009 | December 18, 2009 |
| Vyxeos | daunorubicin and cytarabine | Acute myeloid leukemia | Active | January 22, 2021 | ||
| Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | November 23, 2018 | July 24, 2019 |
| Xarelto | Rivaroxaban | Venous thromboembolism, prevention | Complete | June 24, 2011 | ||
| Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | May 7, 2008 | December 17, 2008 |
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | Complete | October 10, 2012 | ||
| Xarelto | rivaroxaban | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. | Reimburse with clinical criteria and/or conditions | Complete | May 24, 2018 | November 20, 2018 |
| Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | March 18, 2013 | July 18, 2013 | |
| Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | May 6, 2013 | March 26, 2014 |
| Xarelto | Rivaroxaban | Atrial fibrillation, stroke prevention | List with clinical criteria and/or conditions | Complete | October 21, 2011 | April 19, 2012 |
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | List with clinical criteria and/or conditions | Complete | February 27, 2012 | August 16, 2012 |
| Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete | May 5, 2014 | April 17, 2015 |
| Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | June 27, 2018 | February 27, 2019 |
| Xeljanz | tofacitinib | Cancelled | ||||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Blepharospasm | List in a similar manner | Complete | June 12, 2009 | December 16, 2009 |
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Cervical Dystonia | List in a similar manner | Complete | June 12, 2009 | December 16, 2009 |
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Spasticity, Post-stroke | Do not list | Complete | June 12, 2009 | December 16, 2009 |
| Xeomin | incobotulinumtoxin A | Chronic sialorrhea associated with neurological disorders | Pending | |||
| Xermelo | telotristat | carcinoid syndrome | Do not reimburse | Complete | September 27, 2018 | June 26, 2019 |
| Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from breast cancer | List with clinical criteria and/or conditions | Complete | July 31, 2015 | February 25, 2016 |
| Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer | List with clinical criteria and/or conditions | Complete | July 31, 2015 | March 23, 2016 |
| XGEVA | Denosumab | Prevention of skeletal-related events due to bone metastases from solid tumours | List with clinical criteria and/or conditions | Complete | June 6, 2011 | November 16, 2011 |
| Xiaflex | Collagenase clostridium histolyticum | Dupuytren’s contracture | List with criteria/condition | Complete | August 30, 2012 | March 27, 2013 |
| XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | January 7, 2016 | July 20, 2016 |
| Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn | November 3, 2006 | ||
| Zytram XL | Tramadol hydrochloride | Pain, acute | Do not list | Complete | March 15, 2007 | September 26, 2007 |
| Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Xolair | Omalizumab | Chronic idiopathic urticaria | List with clinical criteria and/or conditions | Complete | September 22, 2014 | May 7, 2015 |
| Xolair | Omalizumab | Asthma, severe persistent | Cancelled | April 18, 2005 | ||
| Xolair | Omalizumab (Drug Plan Submission) | Asthma, severe persistent | Reimburse with clinical criteria and/or conditions | Complete | November 18, 2015 | May 18, 2016 |
| Xolair | Omalizumab | Asthma, severe persistent | Do not list | Complete | October 13, 2005 | March 7, 2006 |
| Xultophy | insulin degludec + liraglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | January 30, 2019 | October 24, 2019 |
| Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | July 9, 2008 | January 28, 2009 |
| Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | August 29, 2007 | ||
| Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | January 20, 2005 | June 16, 2005 |
| Zavesca | Miglustat | Gaucher disease | Do not list | Complete | May 13, 2004 | November 24, 2004 |
| Zaxine | Rifaximin | Hepatic encephalopathy | List with criteria/condition | Complete | August 5, 2014 | April 16, 2015 |
| Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | January 10, 2008 | August 14, 2008 |
| Zenhale | Mometasone/formoterol | Asthma | List with clinical criteria and/or conditions | Complete | June 6, 2012 | December 19, 2012 |
| Zepatier | Elbasvir/grazoprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | October 27, 2015 | May 19, 2016 |
| Zeposia | ozanimod | Multiple Sclerosis, relapsing - remitting | Active | August 25, 2020 | ||
| Zinbryta | Daclizumab beta | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | December 20, 2016 | June 20, 2017 |
| Zolgensma | onasemnogene abeparvovec | Spinal muscular atrophy (SMA), pediatrics | Active | June 25, 2020 | ||
| Zolinza | vorinostat | Cutaneous T-cell lymphoma | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | NotFiled | ||
| Opdivo | Nivolumab | Metastatic non small cell lung cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 29, 2015 | June 3, 2016 |
| Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 24, 2015 | April 1, 2016 |
| Jakavi | Ruxolitinib | Polycythemia vera | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 27, 2015 | March 3, 2016 |
| Adcetris | Brentuximab vedotin | Notification to Implement Issued | March 15, 2013 | December 5, 2013 | ||
| Arzerra | Ofatumumab | Notification to Implement Issued | April 14, 2014 | January 29, 2015 | ||
| Giotrif | Afatinib | Notification to Implement Issued | June 7, 2013 | May 2, 2014 | ||
| Kadcyla | Trastuzumab emtansine | Notification to Implement Issued | March 15, 2013 | January 10, 2014 | ||
| Nexavar | Sorafenib | Notification to Implement Issued | December 19, 2014 | July 16, 2015 | ||
| Revlimid | Lenalidomide | Notification to Implement Issued | April 5, 2013 | October 22, 2013 | ||
| Treanda (in combination with rituximab) | Bendamustine hydrochloride | Withdrawn | June 27, 2014 | |||
| Tykerb (in combination with Letrozole) | Lapatinib | Notification to Implement Issued | December 14, 2012 | July 5, 2013 | ||
| Votrient | Pazopanib hydrochloride | Notification to Implement Issued Resubmission Complete | July 14, 2011 | January 5, 2012 | ||
| Xalkori | Crizotinib | Notification to Implement Issued | February 17, 2015 | July 21, 2015 | ||
| Zytiga | Abiraterone acetate | Notification to Implement Issued | March 28, 2013 | October 22, 2013 | ||
| Adcetris | Brentuximab vedotin | Withdrawn | April 5, 2016 | |||
| Onivyde | Nanoliposomal Irinotecan | File-Closed Not Submitted | ||||
| Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Notification to Implement Issued | August 9, 2019 | April 2, 2020 | |
| Bosulif (RFA) | Bosutinib | Chronic Myeloid Leukemia | Notification to Implement Issued | April 8, 2019 | ||
| Unituxin | Dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 1, 2018 | March 26, 2019 |
| Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 30, 2018 | May 23, 2019 |
| Keytruda | Pembrolizumab | Nonsquamous NSCLC | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 14, 2018 | May 31, 2019 |
| Keytruda | Pembrolizumab | MUC First line | Do not reimburse | Notification to Implement Issued | February 20, 2019 | October 3, 2019 |
| TBD | Rituximab | File-Closed Not Submitted | ||||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Notification to Implement Issued | May 8, 2018 | November 29, 2018 |
| Blincyto | Blinatumomab | Withdrawn | June 29, 2018 | |||
| Revlimid | Lenalidomide | Multiple Myeloma (+bortezomib+dex) | Do not reimburse | Notification to Implement Issued | June 19, 2019 | |
| Lenvima | Lenvatinib | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | February 8, 2019 | July 24, 2019 |
| Vectibix | Panitumumab | Left Sided Metastatic Colorectal Cancer (mCRC) | Do not reimburse | Notification to Implement Issued | September 8, 2017 | March 29, 2018 |
| Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Notification to Implement Issued | March 15, 2018 | November 1, 2018 |
| Darzalex | Daratumumab | Multiple Myeloma | Do not reimburse | Notification to Implement Issued | April 21, 2016 | December 1, 2016 |
| Lynparza (Resubmission) | Olaparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | March 17, 2017 | September 20, 2017 |
| Opdivo | Nivolumab | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | January 31, 2017 | August 31, 2017 |
| Ninlaro | Ixazomib | Multiple Myeloma | Do not reimburse | Notification to Implement Issued | December 16, 2016 | June 29, 2017 |
| Imbruvica | Ibrutinib | Not Filed | ||||
| Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Notification to Implement Issued | August 26, 2019 | June 4, 2020 | |
| Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Notification to Implement Issued | September 3, 2019 | March 24, 2020 | |
| Odomzo | Sonidegib | Basal Cell Carcinoma | Under Review | June 19, 2020 | ||
| Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | NSCLC | Under Review | June 23, 2020 | ||
| Cabometyx | Cabozantinib | HCC | Notification to Implement Issued | October 16, 2019 | April 22, 2020 | |
| Rozlytrek | Entrectinib | ROS1-positive NSCLC | Notification to Implement Issued | January 8, 2020 | January 27, 2021 | |
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Notification to Implement Issued | April 7, 2020 | November 17, 2020 | |
| Alecensaro | Alectinib | Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 18, 2017 | March 29, 2018 |
| Bavencio | Avelumab | metastatic Merkel Cell Carcinoma (mMCC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 10, 2017 | March 21, 2018 |
| Kyprolis | Carfilzomib | Multiple Myeloma (relapsed) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 9, 2016 | March 30, 2017 |
| Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Notification to Implement Issued | April 9, 2018 | November 29, 2018 |
| Erbitux | Cetuximab | File-Closed Not Submitted | ||||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Non-Small Cell Lung Cancer | Do not reimburse | Notification to Implement Issued | March 31, 2017 | November 2, 2017 |
| Vizimpro | Dacomitinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 19, 2018 | May 31, 2019 |
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 21, 2018 | May 3, 2019 |
| Ibrance (with Faslodex) | Palbociclib (with Fulvestrant) | Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 28, 2018 | May 3, 2019 |
| Velcade | Bortezomib | Notification to Implement Issued | October 29, 2012 | March 25, 2013 | ||
| Votrient | Pazopanib hydrochloride | Notification to Implement Issued Original Submission Complete | February 20, 2013 | August 29, 2013 | ||
| Xtandi | Enzalutamide | Notification to Implement Issued | October 2, 2014 | June 22, 2015 | ||
| Avastin | Bevacizumab | Notification to Implement Issued | October 27, 2014 | March 23, 2015 | ||
| Adcetris | Brentuximab vedotin | Notification to Implement Issued | March 14, 2013 | August 29, 2013 | ||
| Avastin (with capecitabine) | Bevacizumab | Notification to Implement Issued | February 18, 2015 | July 21, 2015 | ||
| Bosulif | Bosutinib | Notification to Implement Issued | May 30, 2014 | April 21, 2015 | ||
| Halaven | Eribulin Mesylate | Notification to Implement Issued | February 9, 2012 | August 2, 2012 | ||
| Perjeta Herceptin Combo Pack | Pertuzumab | Notification to Implement Issued | November 2, 2012 | August 1, 2013 | ||
| Stivarga (CRC) | Regorafenib | Notification to Implement Issued | March 22, 2013 | November 15, 2013 | ||
| Treanda | Bendamustine hydrochloride | Notification to Implement Issued | April 24, 2012 | November 29, 2012 | ||
| Imbruvica | Ibrutinib | Mantle Cell Lymphoma (relapsed/refractory) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | January 29, 2016 | July 19, 2016 |
| Afinitor | Everolimus | Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | May 30, 2016 | December 1, 2016 |
| Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Notification to Implement Issued | April 12, 2016 | September 29, 2016 |
| Vectibix | Panitumumab | Notification to Implement Issued | April 15, 2015 | December 3, 2015 | ||
| Lutathera | Lutetium Lu 177 dotatate | Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | July 30, 2018 | August 1, 2019 |
| Zejula | Niraparib | Ovarian Cancer | Notification to Implement Issued | February 7, 2020 | September 3, 2020 | |
| Lynparza | Olaparib | Newly Diagnosed OC | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 18, 2019 | December 5, 2019 |
| Ninlaro | Ixazomib | Multiple Myeloma (2nd-beyond) | Do not reimburse | Notification to Implement Issued | November 30, 2018 | July 5, 2019 |
| Keytruda | Pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | December 13, 2018 | August 1, 2019 |
| Ogivri | Trastuzumab | Withdrawn | December 18, 2018 | |||
| Adcetris | Brentuximab Vedotin | peripheral T-cell lymphoma (PTCL) | Notification to Implement Issued | October 8, 2019 | June 4, 2020 | |
| Xospata | Gilteritinib | Notification to Implement Issued | October 28, 2019 | May 20, 2020 | ||
| Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Notification to Implement Issued | August 27, 2019 | April 22, 2020 | |
| Atriance | Nelarabine | File-Closed Not Submitted | ||||
| Idhifa | Enasidenib | Acute myeloid leukemia (AML) | Do not reimburse | Notification to Implement Issued | April 5, 2019 | October 31, 2019 |
| Oncaspar | Pegaspargase | Not Filed | ||||
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Suspended | July 29, 2019 | ||
| Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Notification to Implement Issued | May 6, 2020 | January 8, 2021 | |
| Afinitor | Everolimus | Notification to Implement Issued | February 27, 2012 | August 30, 2012 | ||
| Avastin | Bevacizumab | Notification to Implement Issued | November 28, 2014 | June 4, 2015 | ||
| Erbitux | Cetuximab | Notification to Implement Issued | June 10, 2013 | January 10, 2014 | ||
| Inlyta | Axitinib | Notification to Implement Issued | August 16, 2012 | March 7, 2013 | ||
| Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Notification to Implement Issued | December 19, 2014 | July 16, 2015 | ||
| Stivarga (GIST) | Regorafenib | Notification to Implement Issued | October 11, 2013 | May 2, 2014 | ||
| Sutent | Sunitinib malate | Notification to Implement Issued | November 7, 2011 | May 3, 2012 | ||
| Treanda | Bendamustine hydrochloride | Notification to Implement Issued | April 24, 2012 | February 19, 2013 | ||
| Votrient | Pazopanib Hydrochloride | Notification to Implement Issued | June 4, 2012 | November 29, 2012 | ||
| Xtandi | Enzalutamide | Notification to Implement Issued | March 4, 2013 | July 23, 2013 | ||
| Imbruvica | Ibrutinib | Notification to Implement Issued | August 15, 2014 | March 5, 2015 | ||
| Verzenio | Abemaciclib | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | December 3, 2018 | July 5, 2019 |
| Zytiga | Abiraterone | Withdrawn | February 25, 2019 | |||
| Darzalex | Daratumumab | BMP for Multiple Myeloma (newly diagnosed) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | January 4, 2019 | August 29, 2019 |
| Alecensaro | Alectinib | Locally advanced or metastatic ALK+ NSCLC (first line) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | January 15, 2018 | July 25, 2018 |
| Lenvima | Lenvatinib | Notification to Implement Issued | June 8, 2018 | January 4, 2019 | ||
| Demylocan | Decitabine | Not Filed | ||||
| Kadcyla | Trastuzumab Emtansine | Early Breast Cancer (EBC) | Reimburse | Notification to Implement Issued | July 2, 2019 | January 22, 2020 |
| Truxima | Rituximab | File-Closed Not Submitted | ||||
| Stivarga | Regorafenib | Unresectable Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 12, 2017 | April 18, 2018 |
| Kisqali | Ribociclib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 17, 2017 | April 18, 2018 |
| Tecentriq | Atezolizumab | Small Cell Lung Cancer (SCLC) | Do not reimburse | Notification to Implement Issued | March 4, 2019 | January 30, 2020 |
| Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Notification to Implement Issued | November 6, 2017 | July 6, 2018 |
| Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | June 1, 2018 | April 4, 2019 |
| Tecentriq & Avastin | Atezolizumab & Bevacizumab | NSQ-NSCLC | Notification to Implement Issued | November 18, 2019 | July 3, 2020 | |
| Venclexta | Venetoclax Obinutuzumab | Obinutuzumab for CLL | Notification to Implement Issued | April 17, 2020 | November 17, 2020 | |
| Keytruda | Pembrolizumab | Not Filed | ||||
| Rydapt | Midostaurin | Systemic Mastocytosis | Notification to Implement Issued | August 13, 2019 | April 2, 2020 | |
| Imbruvica | Ibrutinib | Not Filed | ||||
| Darzalex | Daratumumab | Rd for MM | Notification to Implement Issued | July 17, 2019 | March 5, 2020 | |
| TBD | Trastuzumab | File-Closed Not Submitted | ||||
| Inlyta (RFA) | Axitinib | Metastatic Renal Cell Carcinoma | Notification to Implement Issued | April 18, 2017 | ||
| Keytruda | Pembrolizumab | classical Hodgkin Lymphoma (cHL) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | July 7, 2017 | January 5, 2018 |
| Rydapt | Midostaurin | Acute Myeloid Leukemia | Reimburse | Notification to Implement Issued | June 12, 2017 | December 19, 2017 |
| Ibrance Resubmission | Palbociclib | Advanced breast cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | June 10, 2016 | November 21, 2016 |
| Opdivo & Yervoy in combo | Nivolumab & Ipilimumab in combo | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | November 30, 2016 | November 30, 2017 |
| Gazyva | Obinutuzumab | Follicular Lymphoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | November 4, 2016 | June 2, 2017 |
| Tagrisso | Osimertinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 1, 2016 | May 4, 2017 |
| Zykadia | Ceritinib | Notification to Implement Issued | June 5, 2015 | December 3, 2015 | ||
| Opdivo | Nivolumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 13, 2015 | April 1, 2016 |
| Opdivo | Nivolumab | Metastatic Renal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | February 24, 2016 | September 1, 2016 |
| Blincyto | Blinatumomab | Notification to Implement Issued | February 24, 2017 | August 23, 2017 | ||
| Polivy | Polatuzumab Vedotin | Diffuse large B-cell lymphoma (DLBCL) | Under Review | September 29, 2020 | ||
| Alunbrig | Brigatinib | (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) | Under Review | September 30, 2020 | ||
| Afinitor | Everolimus | Notification to Implement Issued | September 5, 2012 | March 25, 2013 | ||
| Erivedge | Vismodegib | Notification to Implement Issued | June 14, 2013 | January 10, 2014 | ||
| Istodax | Romidepsin | Notification to Implement Issued | December 1, 2014 | May 19, 2015 | ||
| Pomalyst | Pomalidomide | Notification to Implement Issued | January 13, 2014 | July 31, 2014 | ||
| Stivarga Resubmission (CRC) | Regorafenib | Notification to Implement Issued | December 19, 2014 | July 16, 2015 | ||
| Sylvant | Siltuximab | Notification to Implement Issued | January 30, 2015 | June 22, 2015 | ||
| Treanda | Bendamustine hydrochloride | Notification to Implement Issued | April 24, 2012 | November 29, 2012 | ||
| Xalkori | Crizotinib | Notification to Implement Issued Original Submission Complete | March 26, 2012 | October 4, 2012 | ||
| Yervoy | Ipilimumab | Notification to Implement Issued | December 1, 2011 | April 18, 2012 | ||
| Zaltrap | Aflibercept | Notification to Implement Issued | November 26, 2013 | September 5, 2014 | ||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Notification to Implement Issued | February 13, 2015 | July 21, 2015 | ||
| Zykadia (Resubmission) | Ceritinib | metastatic non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 19, 2016 | March 21, 2017 |
| Lorbrena | Lorlatinib | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse | Notification to Implement Issued | June 11, 2019 | January 30, 2020 |
| Zevalin | Ibritumomab tiuxetan | Not Filed | ||||
| Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | Advanced or Metastatic Renal Cell Carcinoma (RCC). | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 26, 2018 | November 1, 2018 |
| Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 16, 2018 | November 1, 2018 |
| Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Notification to Implement Issued | August 26, 2019 | April 22, 2020 | |
| Tecentriq | Atezolizumab | Withdrawn | October 2, 2019 | |||
| Keytruda | Pembrolizumab | For locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | July 24, 2017 | March 2, 2018 |
| Venclexta in combo Rituximab | Venetoclax | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 24, 2018 | May 31, 2019 |
| Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 27, 2018 | March 7, 2019 |
| Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 21, 2018 | May 3, 2019 |
| Keytruda | Pembrolizumab | Squamous NSCLC | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | February 8, 2019 | January 3, 2020 |
| Tecentriq | Atezolizumab | Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | December 15, 2017 | June 20, 2018 |
| Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Notification to Implement Issued | February 25, 2019 | October 31, 2019 |
| TBD | Bevacizumab | File Closed | March 14, 2019 | |||
| Imbruvica | Ibrutinib | Chronic Lymphocytic Leukemia (previously untreated) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 20, 2016 | November 3, 2016 |
| Venclexta | Venetoclax | Withdrawn | July 8, 2016 | |||
| Lenvima | Lenvatinib | Differentiated Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 18, 2016 | September 20, 2016 |
| Imbruvica | Ibrutinib | Waldenstrom's Macroglobulinemia | Do not reimburse | Pending | April 21, 2016 | November 3, 2016 |
| Caprelsa | Vandetanib | Medullary Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 15, 2016 | March 30, 2017 |
| Keytruda | Pembrolizumab | Notification to Implement Issued | April 16, 2015 | November 16, 2015 | ||
| Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Notification to Implement Issued | December 22, 2015 | August 5, 2016 |
| Cotellic | Cobimetinib | Metastatic melanoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | December 11, 2015 | June 30, 2016 |
| Kyprolis (with lenalidomide) | Carfilzomib (with lenalidomide) | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | December 11, 2015 | June 21, 2016 |
| Lartruvo | Olaratumab | Advanced Soft Tissue Sarcoma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 26, 2017 | April 18, 2018 |
| Opdivo | Nivolumab | classical Hodgkin Lymphoma (cHL) after failure of ASCT | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 29, 2017 | May 3, 2018 |
| Darzalex | Daratumumab | Multiple Myeloma (second-line) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | March 3, 2017 | October 5, 2017 |
| Adcetris | Brentuximab Vedotin | Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) | Notification to Implement Issued | April 2, 2020 | December 3, 2020 | |
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Notification to Implement Issued | April 7, 2020 | January 8, 2021 | |
| Tecentriq & Avastin | Atezolizumab & Bevacizumab | Hepatocellular Carcinoma (HCC) | Notification to Implement Issued | May 21, 2020 | November 17, 2020 | |
| Onivyde | Irinotecan Liposome | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 27, 2017 | January 5, 2018 |
| Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | May 16, 2018 | January 4, 2019 |
| Beleodaq | Belinostat | Withdrawn | June 29, 2018 | |||
| Keytruda | Pembrolizumab | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | April 21, 2016 | November 3, 2016 |
| Alecensaro | Alectinib | Non-Small Cell Lung Cancer | Do not reimburse | Notification to Implement Issued | October 3, 2016 | May 4, 2017 |
| Blincyto (Resubmission) | Blinatumomab | Acute Lymphoblastic Leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | February 24, 2017 | August 31, 2017 |
| Venclexta | Venetoclax | Chronic Lymphocytic Leukemia | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | July 10, 2017 | March 2, 2018 |
| TBD | Cabozantinib | Withdrawn | October 6, 2017 | |||
| Besponsa | Inotuzumab Ozogamicin | Acute Lymphoblastic Leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | November 13, 2017 | July 6, 2018 |
| Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | March 15, 2019 | September 18, 2019 |
| Nerlynx | Neratinib | ERBB2-positive breast cancer | Do not reimburse | Notification to Implement Issued | April 18, 2019 | December 5, 2019 |
| Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Notification to Implement Issued | April 1, 2016 | September 29, 2016 |
| Cyramza | Ramucirumab | File-Closed Not Submitted | ||||
| Adcetris | Brentuximab Vedotin | HL at high risk of relapse or progression post-ASCT | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 10, 2017 | February 21, 2018 |
| Faslodex | Fulvestrant | Locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | July 17, 2017 | February 1, 2018 |
| Rituxan | Rituximab | Acute Lymphoblastic Leukemia | Do not reimburse | Notification to Implement Issued | February 13, 2017 | August 31, 2017 |
| Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 17, 2018 | February 20, 2019 |
| Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | September 24, 2018 | March 26, 2019 |
| Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Notification to Implement Issued | August 27, 2018 | March 7, 2019 |
| Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | August 31, 2018 | April 4, 2019 |
| Alunbrig | Brigatinib | NSCLC | Do not reimburse | Notification to Implement Issued | December 5, 2018 | August 1, 2019 |
| Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | Final Biosimilar Dossier Issued | October 3, 2018 | ||
| Libtayo | Cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma (CSCC) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | July 9, 2019 | January 22, 2020 |
| Abraxane | Nab-paclitaxel | Notification to Implement Issued | February 14, 2014 | September 23, 2014 | ||
| Alimta | Pemetrexed | Notification to Implement Issued | May 31, 2013 | November 19, 2013 | ||
| Gazyva | Obinutuzumab | Notification to Implement Issued | August 11, 2014 | January 27, 2015 | ||
| Jakavi | Ruxolitinib | Notification to Implement Issued | June 25, 2012 | January 14, 2013 | ||
| Mekinist | Trametinib | Notification to Implement Issued | May 6, 2013 | October 22, 2013 | ||
| Proleukin | Aldesleukin (IL-2) | Notification to Implement Issued | January 30, 2015 | June 22, 2015 | ||
| Tafinlar | Dabrafenib | Notification to Implement Issued | March 18, 2013 | December 5, 2013 | ||
| Trisenox | Arsenic Trioxide | Notification to Implement Issued | August 30, 2013 | February 18, 2014 | ||
| Xalkori | Crizotinib | Notification to Implement Issued Original Submission Complete | October 23, 2012 | May 2, 2013 | ||
| Yervoy | Ipilimumab | Notification to Implement Issued | August 15, 2014 | December 22, 2014 | ||
| Zelboraf | Vemurafenib | Notification to Implement Issued | December 6, 2011 | June 1, 2012 | ||
| Avastin | Bevacizumab | Platinum Resistant Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | October 29, 2015 | May 5, 2016 |
| Ibrance | Palbociclib | Suspended | November 11, 2015 | |||
| Cyramza | Ramucirumab | Notification to Implement Issued | April 15, 2015 | October 29, 2015 | ||
| Iclusig | Ponatinib | Notification to Implement Issued | March 13, 2015 | October 1, 2015 | ||
| Zydelig | Idelalisib | Notification to Implement Issued | April 7, 2015 | August 18, 2015 | ||
| Revlimid | Lenalidomide | Notification to Implement Issued | May 4, 2015 | December 3, 2015 | ||
| Keytruda | Pembrolizumab | Advanced non-small cell lung carcinoma (first line) | Reimburse with clinical criteria and/or conditions | Notification to Implement Issued | December 12, 2016 | August 23, 2017 |
| Avastin | Bevacizumab | Withdrawn | December 16, 2016 | |||
| Lonsurf | Trifluridine and Tipiracil | mCRC Resubmission | Do not reimburse | Notification to Implement Issued | January 21, 2019 | August 29, 2019 |
| TBD | Entrectinib | Withdrawn | July 29, 2019 | |||
| Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Notification to Implement Issued | August 2, 2019 | April 2, 2020 | |
| Xtandi | Enzalutamide | mHSPC | Notification to Implement Issued | February 24, 2020 | September 23, 2020 | |
| Keytruda | Pembrolizumab | Not Filed | ||||
| Erleada | Apalutamide | metastatic castration-sensitive prostate cancer (mCSPC) | Notification to Implement Issued | October 15, 2019 | April 22, 2020 | |
| Blincyto | Blinatumomab | MRD+ ALL Resubmission | Notification to Implement Issued | January 20, 2020 | October 29, 2020 | |
| Adcetris | Brentuximab Vedotin | Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) | Notification to Implement Issued | March 30, 2020 | December 3, 2020 | |
| Lynparza | Olaparib | Not Filed | ||||
| Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Notification to Implement Issued | May 1, 2020 | December 22, 2020 | |
| Sarclisa | Isatuximab | Multiple Myeloma | Under Review | August 17, 2020 | ||
| Lynparza | Olaparib | metastatic castration-resistant prostate cancer (mCRPC) | Under Review | September 22, 2020 | ||
| Inqovi | Decitabine-Cedazuridine | Myelodysplastic Syndromes (MDS) | Under Review | October 9, 2020 | ||
| Tafinlar and Mekinist | Dabrafenib and Trametinib | NSCLC BRAF V600 | Under Review | October 1, 2020 | ||
| Bavencio | Avelumab | Urothelial Carcinoma (UC) | Under Review | September 18, 2020 | ||
| Zejula | Niraparib | First Line OC | Under Review | September 21, 2020 |